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We have studied a family with severe mental retardation characterized by the virtual absence of speech, autism spectrum
disorder, epilepsy, late-onset ataxia, weakness and dystonia. Post-mortem examination of two males revealed widespread
neuronal loss, with the most striking finding being neuronal and glial tau deposition in a pattern reminiscent of corticobasal
degeneration. Electron microscopic examination of isolated tau filaments demonstrated paired helical filaments and ribbon-like
structures. Biochemical studies of tau demonstrated a preponderance of 4R tau isoforms. The phenotype was linked to Xq26.3,
and further analysis identified an in-frame 9 base pair deletion in the solute carrier family 9, isoform A6 (SLC9A6 gene), which
encodes sodium/hydrogen exchanger-6 localized to endosomal vesicles. Sodium/hydrogen exchanger-6 is thought to participate
in the targeting of intracellular vesicles and may be involved in recycling synaptic vesicles. The striking tau deposition in our
subjects reveals a probable interaction between sodium/proton exchangers and cytoskeletal elements involved in vesicular
transport, and raises the possibility that abnormalities of vesicular targeting may play an important role in more common
disorders such as Alzheimer’s disease and autism spectrum disorders.
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Abbreviations: PHF = paired helical filaments; SDS–PAGE = sodium dodecyl sulphate polyacrylamide gel electrophoresis;
SLC9A6 = solute carrier family 9, isoform A6; TDP-43 = transactivation response element DNA-binding protein
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Introduction
Mental retardation affects an estimated 2–3% of the population.
About 25% of mental retardation is believed to be caused by
genetic abnormalities, and up to 10% is estimated to be caused
by X chromosome mutations, accounting in part for the observed
male preponderance of mental retardation (reviewed in Ropers,
2006). While fragile X mental retardation-1 is the most common
cause of hereditary mental retardation, many other X chromosome
mental retardation loci have been characterized. Over 50 genes
have been identified that are associated with syndromic, or clinic-
ally distinctive, X-linked mental retardation, and over 15 genes
have been found to be associated with non-syndromic, or clinically
indistinguishable X-linked mental retardation (http://
www.ggc.org/xlmr.htm). Over 100 additional X chromosome
loci have been linked to non-syndromic and syndromic mental
retardation for which the genes have not yet been identified.
Since the candidate chromosomal loci for some of these families
overlap, and allelic heterogeneity can occur, it is possible that this
number may be an overestimate. The distinction between syn-
dromic and non-syndromic mental retardation is not precise, and
conditions previously regarded as non-syndromic forms of mental
retardation may have additional clinical findings that were not
initially recognized or emphasized, such as the cerebellar hypopla-
sia seen in mutations of the oligophrenin 1 (OPHN1) gene (Philip
et al., 2003).
Here, we report a family with a novel, syndromic form of severe
X-linked mental retardation with autistic behaviour, seizures and
wide-spread neuronal degeneration that is associated with fila-
mentous neuronal and glial deposits of the microtubule-binding
protein tau in cortical and sub-cortical regions. Tau-positive inclu-
sions are the defining neuro-pathological characteristics of a
number of adult-onset neuro-degenerative disorders (subsumed
as tauopathies), including Alzheimer’s disease, progressive supra-
nuclear palsy, corticobasal degeneration and Pick disease, as well
as familial forms of fronto-temporal dementia (FTDP-17T), which
are associated with mutations in the gene that encodes tau, MAPT
(Sima et al., 1996; Lee et al., 2001). The central nervous system
(CNS) tau pathology in two affected members of this family with
X-linked mental retardation was analysed using histological,
immuno-histochemical, biochemical and ultrastructural methods.
Our data demonstrate that solute carrier family 9, isoform A6
(SLC9A6)-related mental retardation can be associated with a
tauopathy characterized by neuronal and glial tau inclusions. To
our knowledge these tau-positive inclusions have not been asso-
ciated with early-onset mental retardation or autism.
Materials and methods
Clinical
Subjects were evaluated through an Institutional Review
Board-approved protocol, and consent for blood testing and autopsy
was obtained from the subjects’ parents or guardians.
Linkage analysis
Twenty-nine evenly spaced microsatellite markers on the X chromo-
some were genotyped. The forward primers were synthesized with a
fluorescein-tag (Fluore Prime, Amersham) at the 50-end. Microsatellite
polymorphisms were analysed on the CEQ 8800 (Beckman Coulter)
using the Fragment manager software. Two-point and multipoint link-
age analyses were performed using Perl scripts (available for download
at http://bioinfo.ggc.org/ggcepi/linkage.html) that automate the use
of the FASTLINK package (Lathrop et al., 1984; Cottingham et al.,
1993). The disease gene frequency was set at 0.0001, and full pene-
trance in males and no penetrance in females were assumed. Once a
linked region was observed, the region was further refined by geno-
typing and analysing additional markers.
Mutation screening
The coding exons and their flanking regions of SLC9A6 were amplified
from genomic DNA and sequenced using an Applied Biosystems 3730
automated DNA Analyser. Sequencing was performed in both directions.
MAPT genetic analysis
Genomic DNA was extracted from frozen brain tissue using a magnetic
particle-based system (MagAttract DNA M48 Mini kit; Qiagen,
Chatsworth, CA, USA) on an automated platform (BioRobot M48;
Qiagen) according to the manufacturer’s protocol. Exons 1, 913 of
the MAPT gene were amplified for direct DNA sequencing using pri-
mers corresponding to flanking intronic sequences.
Pathological analysis
The brains from two cases, III-9 and III-11, were examined pathologic-
ally. At the time of autopsy, the brains were weighed and samples
were obtained from various regions and snap-frozen in liquid nitrogen.
The brains were then suspended in 10% buffered formalin for at least
2 weeks. At brain cutting, the gross aspects of the brain were re-
corded. Routine histological analysis was performed on paraffin-
embedded material and stained with haematoxylin–eosin, luxol fast
blue, Bielchowsky’s silver stain and Congo red according to standard
clinical protocols.
Immunohistochemistry
Formalin-fixed tissue samples were paraffin embedded, and cut into
6 mm thick sections. Immuno-histochemistry was performed as previ-
ously described using the ABC method (Vectastatin ABC kit, Vector
Laboratories, Burlingame, CA, USA) and 3,30-diaminobenzidine
(Schmidt et al., 1987; Mawal-Dewan et al., 1996; Forman et al.,
2002). The following primary antibodies were used: anti-human
neurofilament-L monoclonal mouse antibody, clone 2F11 (1:100;
Dako AS, Glostrup, Denmark), anti-tau monoclonal mouse antibodies
paired helical filament (PHF)-1 (1:1000, gift from P. Davies, Albert
Einstein College of Medicine, Bronx, NY, USA) (Greenberg and
Davies, 1990) and AT-8 (1:1000) (Mercken et al., 1992; Goedert
et al., 1995), affinity-purified polyclonal anti-tau antibody
17025 (1:3000) (Zhukareva et al., 2002), anti--synuclein mono-
clonal mouse antibody LB509 (1:1000) (Giasson et al., 2000) and
anti-transactivation response element DNA binding protein (TDP-43)
polyclonal antibody (1:1000; ProteinTech Group, Chicago, IL, USA).
The sections were viewed with a Nikon FXA microscope and images
were captured with the RS Image software (Roper Scientific Inc.,
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Duluth, GA, USA). For semi-quantitative assessments of the different
pathological abnormalities, the scoring was defined as: 0 = none,
1 = mild, 2 = moderate and 3 = severe.
Biochemical and western blot analysis
Frozen tissue samples for biochemical analysis were available from
frontal and occipital cortices of Case III-9 and frontal cortex, basal
ganglia and cerebellum of Case III-11.
Phosphorylated and dephosphorylated sarkosyl-insoluble samples
were prepared as previously described (Lee et al., 1991; Hong
et al., 1998; Winton et al., 2006). The solubility profile of tau was
analysed on sequential extractions of brain samples using methods
reported earlier (Forman et al., 2002). For western blot analysis, pro-
tein extracts were resolved by 7.5% sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS–PAGE) and transferred to
nitrocellulose membranes and probed with a mixture of anti-tau
monoclonal antibodies T14 (1:3000) (Kosik et al., 1988; Hong et al.,
1998) and T46 (1:1000) (Kosik et al., 1988; Hong et al., 1998) as well
as phosphorylation-dependent anti-tau monoclonal antibodies AT8
(Goedert et al., 1993) (1:500, Innogenetics, Ghent, Belgium), PHF-1
(Greenberg and Davies, 1990) (1:500, gift from Dr P. Davies, Albert
Einstein College of Medicine, Bronx, NY, USA) and 12E8 (Seubert
et al., 1995) (1:1000, gift from Dr P. Seubert, Elan Pharmaceuticals,
South San Francisco, CA, USA). Six recombinant human brain
tau isoforms were used as a standard for the western blot
studies. Monoclonal antibodies were detected with horseradish
peroxidase-conjugated anti-mouse immunoglobulin G (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA) and signals were revealed by
a horseradish peroxidase-based chemiluminescent reaction (Pierce,
Rockford, IL, USA).
Electron microscopy of isolated
filaments
Dispersed tau filaments were prepared from separately dissected cor-
tical grey and white matter, adsorbed on carbon-coated 400-mesh
grids, and stained with 0.4% uranyl acetate as described (Zhukareva
et al., 2002). Grids were examined with a JEM1010 electron micro-
scope at 80 kV.
Results
Clinical description of the family
The pedigree of this family is shown in Fig. 1. The family is of
mixed, non-consanguineous English, Welsh and Scottish descent.
At least six males had severe mental retardation that was apparent
during early childhood, with little to no language acquisition, but
relatively preserved gross motor development. The affected males
displayed little interest in social interaction and did not play with
family or schoolmates. They displayed little emotional response
and remained aloof. The affected individuals were graded as se-
verely autistic using the Childhood Autism Rating Scale (Schopler
et al., 1980). Several of the affected males had stereotyped,
repetitive hand movements, reminiscent of patients with Rett syn-
drome. Progressive motor deterioration and ataxia were observed
in the affected males beginning in the fourth to fifth decade of
life. In two of the affected males, unilateral weakness and spasti-
city developed prior to the loss of ambulation. The MRI of Patient
III-9 did not show cerebellar atrophy of significant structural
anomalies, except for an incidental cavernous haemangioma and
moderate atrophy (Fig. 2).
Linkage analysis
Linkage mapping using 29 microsatellite markers on the
X chromosome localized the disease locus in family K9071 between
markers DXS1047 (Xq26.1) and DXS8106 (Xq27.1), an interval of
13.1 Mb (Supplementary Table 1). A maximum LOD score of 2.0
was obtained for DXS994, DXS8041, DXS1192 and DXS984.
Multipoint analysis yielded a maximum LOD score of 2.4
(Supplementary Fig. 1) and the disease locus was tightly linked be-
tween markers DXS984 and DXS994, an interval of 9.3 Mb. One
hundred and seventeen genes have been identified in this area.
Among these are genes already known to be involved in X-linked
mental retardation, such as GPC3, PHF6, ARJGEF6, FGF13,
SLC9A6, PIX, ZDHHC9, HPRT, OCRL1 and SOX3.
Other candidate genes from the area include two genes that
Figure 1 Pedigree of the family. Patient IV-8 is mildly retarded but has acquired good language skills. Patient V-3, by age 5 years, had
acquired some receptive language ability, was able to operate a videotape player and other household appliances and had been diagnosed
as mildly autistic, and is highlighted by the corner square. The propositus is indicated by an arrow. The subjects who were examined and
from whom DNA samples were obtained are indicated by a dot to the lower left of the individual’s icon. Plus symbols indicate individuals
who have the c.1012_1020del mutation in SLC9A6. Female heterozygotes are indicated by the central dot.
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encode the zinc finger proteins, ZNF75 and ZNF449, and two genes
that are expressed in the brain, MST4 and GPC4.
Recently, SLC9A6 mutations have been shown to cause a
severe syndromic form of X-linked mental retardation, in a
family originally described by Christianson et al. (1999). The
phenotypic similarity of affected males in this family to that
described by Christianson et al. and the linkage to Xq26.3 led
to analysis of SLC9A6. Sequencing of the coding sequence of
SLC9A6 using genomic DNA from one affected male in the
family detected a 9 base pair deletion, c.1012_1020del (Refseq
NM_006359.2) in exon 8. Sequence analysis of other members
of the family found this 9 base pair deletion segregated with the
X-linked mental retardation phenotype (Fig. 1). The 9 base pair
deletion results in an in-frame deletion of three amino acids,
p.Trp338_Thr340del (p.Trp392_Thr394del of the longer transcript
refseq NM_001042537). These amino acids fall within a domain,
conserved at least through zebrafish, of SLC9A6 and that abuts
a potential transmembrane domain from amino acid residues
340–360 (394–414).
The clinical findings for all six affected males are summarized in
Table 1 and compared to the clinical findings described by
Christianson et al. (1999) and Gilfillan et al. (2008), who described
three additional families in addition to those originally described
by Christianson et al. (1999). An Angelman-like phenotype
was not observed in any of the affected males. Although head
circumference was below average, microcephaly was not as prom-
inent as observed in the families described by Gilfillan et al.
(2008), whose head circumferences were 2–4 cm, below the 2.5
percentile.
Neuropathological examination
Two members of the family died and, with the family’s informed
consent, post-mortem analysis was conducted. The findings were
similar in the specimens from Patients III-9 and III-11, except for a
left occipital cavernous haemangioma, judged to be a coincidental
finding, in Patient III-9. There was generalized and symmetric
cerebral atrophy, with brain weights of 1020 and 950 g, respect-
ively. Both specimens had generalized atrophy of the white matter
and moderate dilatation of the ventricles. The cortex was unre-
markable and well demarcated. The head of the caudate, putamen
and globus pallidus appeared small and discoloured. Cerebellum
was moderately atrophied. There was pallor of the substantia nigra
and locus coeruleus. The spinal cords were unremarkable. The
most striking histological findings were marked neuronal loss and
gliosis of the globus pallidus, putamen, substantia nigra and cere-
bellar cortex (Fig. 3A and Table 2). Less severe neuronal loss and
gliosis were seen in the caudate nucleus, pontine and inferior oliv-
ary nuclei and in the cerebellar dentate nucleus (Table 2). The
cerebral cortex and hippocampus were only mildly involved
(Table 2). The centrum semiovale, cerebellar and brainstem
Table 1 Clinical features of SLC9A6-related mental retardation
CNS features III-8
53 years
III-9
49 years
III-10
47 years
III-11 IV-4
23 years
IV-5a
22 years
% Christianson
syndrome
Gilfillan et al.
(families 1–3)
Profound mental retardation + + + + + + 100 16/16 (100) 3/3
Autistic behaviour + + + + + + 100 2/4 (50)b
Microcephalyc (55.9) (54) +(53) +(53.3) (55.5) (54) 33 3/4 (75) 3/3
Mutism +  + + +  66.7 16/16 (100) 3/3
Incontinence + + + + + + 100 14/14 (100)
Epilepsy +  + + + + 83.3 14/14 (100) 3/3
Ophthalmoplegia + + + +  + 83.3 3/3 (100) 3/3
Truncal ataxia + + + + + + 100 3/3 (100)
Non-ambulatory       0 7/16 (43.75)
Late ambulation +  + +  + 66.7 9/16 (56.25)
Adducted thumbs       0 5/8 (62.5)
Dystonia + + + + + 83.3
Maladaptive behaviour + + + +   66.7
Hand-wringing + + + +   66.7
Hemiparesis  + +    33.3
Angelman-like syndrome       0 0 3/3
Craniofacial features
Long, narrow face      +a 16.7 5/5 (100) 1/3
Large ears       0 7/7 (100)
Square, prognathic jaw      +a 16.7 5/5 (100)
Long, aquiline nose      +a 16.7 5/5 (100)
Clinical features of the family; percentage of family members with the clinical sign is given in column 8. For comparison, the numbers and percentages (in parentheses) of
family members described by Christianson et al. (1999) and by Gilfillan et al. (2008), are presented in the following two columns. Patient III-11 is deceased and had not
been examined by any of the authors. His clinical findings were obtained from his medical records and examination of photographs.
a Patient also has a chromosomal translocation: 46, XY, t(14;18)(q13;q23).
b Based on the detailed narrative descriptions of four patients.
c Figures in parentheses are occipito-frontal head circumferences (cm). Microcephaly was present if the height-adjusted head circumference was less than the 3rd percentile
for adults, as defined by Bushby et al. (1992).
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white matter tracts showed diffuse glial tau pathology. The spinal
cord was unremarkable except for occasional dystrophic axons in
the anterior and dorsal horns.
Numerous tau-positive inclusions resembling coiled bodies were
seen in glial cells throughout the white matter (Fig. 3B). A striking
finding was widespread, strongly tau-positive tangle-like
inclusions, commonly seen in neurons in the substantia nigra
(Fig. 3C), locus coeruleus, pontine nuclei, basal ganglia, thalami
and cranial nerve nuclei (Fig. 3D and Table 2). These were also
seen in the cerebral cortex and hippocampus (Table 2).
Tau-positive astrocytic plaques were seen in the cerebral white
matter, thalamus and brainstem (Fig. 3E). Tau-positive inclusions
Figure 2 Representative MRI slices from Patient III-9. (A) Axial T2-weighted image showing moderate ventricular enlargement and sulcal
widening with normal appearance of white matter. (B) Axial T2-weighted image at level of midbrain. In addition to the atrophied
appearance of the brain, there is a left parieto-occipital lesion (arrowhead) with evidence of surrounding past haemorrhage (dark rim).
(C) Gadolinium enhanced T1-weighted slice showing enhancement of the left parieto-occipital lesion (arrowhead). (D) T1 sagittal slice
through the midline showing thin corpus callosum and moderate sulcal prominence and ventricular dilatation.
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stained almost equally well with Bielschowsky’s silver stain
(Fig. 3F). Neuronal inclusions stained less well for phosphorylated
neurofilaments. No -synuclein or TDP-43 positive inclusions, bal-
looned neurons or amyloid deposits were identified. The patho-
logical findings are summarized in Table 2.
Biochemical and ultrastructural analyses
of tau
To assess the tau isoform composition, sarcosyl-insoluble tau
was extracted from affected cortical and sub-cortical brain re-
gions of Patients III-9 and III-11. Immunoblotting with
phosphorylation-independent anti-tau monoclonal antibodies,
resolved sarkosyl-insoluble tau into two major bands of 64 and
69 kD and a weaker band of 60 kD (Fig. 4A). In dephosphory-
lated samples, tau isoforms comprised a mixture of 3R and 4R
isoforms. However, a clear preponderance of 4R isoforms (4R0N
and 4R1N) was evident in extracts from affected cortical and
sub-cortical brain regions in both cases (Fig. 4A). While the 4R
to 3R isoform ratio in Alzheimer’s disease and control brains is 1
(Hong et al., 1998; Zhukareva et al., 2002), quantitative analysis
of the band intensities revealed an increase of the 4R to 3R ratio
up to 2.4 (frontal grey) and 2.2 (frontal white) in Cases III-9 and
2.4 (basal ganglia) in Case III-11.
Ultrastructural analysis of the tau filaments in the
sarkosyl-insoluble material revealed a mixture of PHF-like struc-
tures (maximum width 15–20 nm, distance between crossovers
70–80 nm) and ribbon-like structures (maximum width
17–22 nm, distance between crossovers 150–240 nm; Fig. 4B).
To characterize pathological tau proteins further in these cases,
we conducted studies of a wide spectrum of tau proteins ranging
from soluble to very insoluble species using a graded sequential
Figure 3 Histological and immunohistochemical analyses. (A) Cerebellar cortex from Patient III-9 showing severe loss of Purkinje cells and
neuronal loss in the internal granular layer. Haematoxylin–eosin stain, scale bar = 300 mm. (B) Cerebral white matter from Patient III-11
stained with anti-tau showing diffuse abundant positive staining of white matter glial elements. Scale bar = 100 mm. (C) Tau-stained
substantia nigra from Patient III-9 showing frequent tau-positive neuronal inclusions. Scale bar = 20 mm. (D) Tau immunostaining of the
third cranial nerve nucleus from Patient III-11 shows abundant positive staining of the neuronal population. Scale bar = 200 mm. (E)
Tau-positive astrocytic plaque (arrowhead) in the dorsal raphae nucleus in Patient III-9. Scale bar = 20 mm. (F) Bielschowsky silver stain of
the dentate nucleus of the cerebellum in Patient III-11 showing frequent silver-positive neuronal inclusions. Scale bar = 50 mm.
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series of buffers containing detergents or acids with an increasing
ability to solubilize proteins. Highly insoluble tau species as re-
covered by extraction with 2% SDS buffers were detected in af-
fected cortical regions in Cases III-9 and III-11 revealing a double
band of 64 and 69 kD as well as a high molecular mass smear
(Fig. 5A). Western blot analysis with phosphorylation-dependent
monoclonal antibodies PHF-1, AT8 and 12E8 showed robust label-
ling of the 64 and 68 kD bands, and the high molecular mass
smear demonstrated that insoluble tau in the studied cases was
highly phosphorylated (Fig. 5B).
Molecular genetic analyses
Chromosome analysis of Patient IV-5 revealed an apparently
balanced translocation: 46, XY, t(14;18)(q13;q23); however, this
was not present in his mother, or in Patients III-9 or IV-4.
Mutations in the MECP2 gene, including deletion and duplication
of the entire gene, were excluded as was expansion of the Fragile
X mental retardation trinucleotide repeat region. To exclude the
possibility that the tauopathy in this family is due to a mutation in
the tau gene, all exons of the MAPT gene in which mutations
have been described in familial forms of fronto-temporal dementia
so far were sequenced. No mutation was found in the two studied
family members described here.
Discussion
The present study describes a novel family with syndromic
X-linked mental retardation and autism associated with tau path-
ology in neurons and glial cells. Clinically, the affected males had
severe mental retardation and autistic behaviour, but relative spar-
ing of gross motor abilities (Table 1). Additional clinical signs
found in most of the affected males included seizures and late,
progressive ataxia that began in the fourth decade. We attribute
the dysmorphic features in Patient IV-5 to a chromosomal re-
arrangement that was not present in the other affected relatives,
and which we believe was an independent and unrelated anomaly,
Table 2 Severity of neuronal loss and gliosis and frequencies of tau-positive and Bielchowsky-positive neuronal and glial
inclusions as well as phosphorylated neurofilament inclusions
Neuronal loss Glial fibrillary
acidic protein
Bielschowsky Tau Neurofilament
Neurons Glia Neurons Glia
Cortex
Frontal 0.5 1.0 1.5 1.0 1.5 1.5 1.0
Entorhinal 1.0 1.5 2.0 1.0 2.0 0.5 1.0
Parietal 0 0.5 1.5 1.0 1.0 0.5 1.0
Occipital 0.5 0.5 1.0 0.5 1.0 2.0 1.5
Hippocampus
CA1 1.0 2.0 1.0 0.5 1.5 0.5 0.5
CA2 0.5 1.0 0.5 0.5 1.0 0.5 0.5
CA3 0 0.5 0.5 0.5 1.5 0.5 0.5
CA4 0.5 2.0 0.5 0.5 0.5 0.5 1.0
Subiculum 0.5 2.0 2.0 1.0 2.0 0.5 1.0
Basal ganglia
Putamen 2.0 1.5 2.0 2.0 2.0 1.0 0.5
Caudate 1.0 2.0 2.0 1.0 2.0 2.0 1.0
Globus pallidus 2.5 2.0 2.0 1.0 2.0 1.5 2.0
Thalamus
Lateral 0.5 1.5 1.0 1.0 2.0 3.0a 0.5
Dorsomedial 1.0 1.5 1.5 1.0 0.5 1.5a 0.5
Brainstem
Substantia nigra 2.5 2.5 2.5 1.5 3.0 2.0 2.0
Third nucleus 1.0 2.0 2.0 0.5 1.5 2.0 0
Fourth nucleus 0.5 1.0 1.5 0.5 1.5 1.5 0
Locus ceruleus 1.5 2.0 2.0 1.0 2.5 2.0a 0.5
Fifth nucleus 1.5 1.5 2.5 2.5 1.5 1.5 1.0
Pontine nuclei 1.0 1.5 1.0 0.5 1.5 1.5a 0.5
Olivary nucleus 1.0 0.5 1.5 1.5 0.5 2.0 1.5
Cerebellum
Cortex 2.5 3.0 0 0 0 0 0
Dentate 2.0 2.0 1.5 1.5 2.0 2.0a 0.5
The numbers represent severity: 0 = none; 1 = mild; 2 = moderate; 3 = severe. Each number represents the mean of Cases III-9 and III-11.
a Represents presence of tau-positive glial plaques.
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as we also believe was the finding of a cavernous haemangioma in
Patient III-9. Since all but one patient had a seizure disorder, and
all of the older patients had late onset (after the fourth decade)
clinical deterioration, we consider this to be a syndromic form of
X-linked mental retardation. The learning disorder present in IV-6
may be caused by unfavourably skewed X-inactivation, dominant
inheritance with low penetrance in heterozygous females, variable
expressivity or other genetic and non-genetic factors.
We found the family’s disorder was caused by a mutation in
SLC9A6. The syndrome shared profound mental retardation with
severe language disturbance with the families described by
Christianson et al. (1999) and Gilfillan et al. (2008). However,
the mild dysmorphic features described by Christianson and an
Angelman-like syndrome were not observed in the family reported
here. Microcephaly was observed in two of the subjects, and does
not appear to be as striking as that observed in the patients
described by Gilfillan et al. (2008). One patient (IV-5) with dys-
morphic features also had a coincidental chromosomal transloca-
tion not present in other affected family members. The affected
males in the family did not play or interact significantly with family
members or schoolmates as children or adults. An autistic pheno-
type was also described in two of the subjects described by
Christianson et al. (1999).
Pathological findings in two of the decedents were quite wide-
spread and intriguing. Besides neuronal loss and gliosis, which
were most predominant in the cerebellar cortex, substantia
nigra, putamen, globus pallidus and dentate nucleus of the cere-
bellum, the most striking neuropathological features were wide-
spread neuronal and glial tau pathology. Tangles were especially
prominent in substantia nigra, putamen, globus pallidus and sub-
stantia innominata, subiculum, entorhinal cortex and the dentate
nucleus. Interestingly, the severity of neuronal loss did not correl-
ate with the amount of tau immunoreactivity. Cortical neuronal
loss was mild, but there was moderate tau deposition in both
neurons and glia. In contrast, cerebellar neuronal tau deposits
were not observed in the cortex, although there was severe cor-
tical neuronal loss. This finding has also been observed in other
tauopathies, possibly because the cerebellum has a lower
Figure 4 (A) Isoform composition of sarkosyl-insoluble tau.
Frozen tissue from frontal grey (Fg) and white (Fw) matter and
basal ganglia (BG) from Case III-9 were used to extract
sarkosyl-insoluble tau species. A portion of each sample was
dephosphorylated by incubation with alkaline phosphatase (AP).
The dephosphorylated (AP +) and non-dephosphorylated (AP)
samples plus a mixture of six recombinant human brain tau
isoforms were resolved on 7.5% SDS–PAGE and immunoblotted
with a mixture of monoclonal antibodies T14 and T46. (B–D)
Ultrastructural analysis of isolated tau filaments revealing
paired-helical filament-like structures (B and C) as well as
ribbon-like structures (D).
Figure 5 (A) Solubility profile of tau proteins. Frontal grey (Fg)
and white (Fw) matter from Case III-9 as well as basal ganglia
(BG) from Case III-11 were used for sequential extraction of tau
with buffers of increasing stringency. Proteins in each fraction
were separated by SDS–PAGE and immublotted with a mixture
of monoclonal antibodies T14 and T46. 1 = high-salt; 2 = 1%
Triton-X100; 3 = radioimmunoprecipitation assay buffer; 4 = 2%
SDS; 5 = 70% formic acid fractions. (B) Insoluble tau proteins in
the 2% SDS fractions are hyperphosphorylated as shown by
immunoblotting with phosphorylation-specific monoclonal
antibodies PHF1, AT8 and 12E8.
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endogenous tau content than do other brain regions (Bu et al.,
2002).
The two patients described here showed neuropathological
changes reminiscent of those characterizing corticobasal degener-
ation (Dickson et al., 2002). Similar to corticobasal degeneration,
they showed severe neuronal loss of globus pallidus as well as of
the substantia nigra, and moderate neuronal loss in the frontal and
occipital cortices and subiculum and thalamic nuclei. These
changes were associated with abundant neuronal and glial tau
pathology, including coiled bodies and astrocytic plaques that
are the characteristic features of corticobasal degeneration. Glial
tau-positive inclusions resembling coiled bodies have been
described in the white matter of patients with fronto-temporal
lobar dementia (Kovacs et al., 2008); however, this globular
type of glial inclusion was not seen in our two cases.
In contrast to the characteristic findings in corticobasal degen-
eration, ballooned neurons that are a key feature of corticobasal
degeneration were not identified in cerebral cortex or hippocam-
pus for any of the subjects described here. Furthermore, the neur-
onal loss was most pronounced in hippocampal CA4 and
subiculum as opposed to CA2 and CA3 as in corticobasal degen-
eration. Another distinct difference was the severe degeneration of
cerebellar Purkinje cells and dentate nuclear neurons not usually
seen in corticobasal degeneration (Brown et al., 1996; Ikeda,
1997; Mori and Oda, 1997; Armstrong et al., 2000; Dickson
et al., 2002).
Corticobasal degeneration is known to demonstrate both clinical
and pathological variability, but is clinically distinct from the clinical
syndrome demonstrated by the family we report here.
Corticobasal degeneration is a disorder of late middle age charac-
terized by clumsiness that typically begins on the non-dominant
side, bradykinesia, dystonia, reflex myoclonus, dysarthria, ideomo-
tor apraxia and relatively late-onset dementia (Litvan et al., 1998;
Mahapatra et al., 2004; Belfor et al., 2006). Although rare, famil-
ial occurrences of corticobasal degeneration have been reported,
some caused by mutations affecting the GRN (formerly PGRN, or
progranulin) gene (Masellis et al., 2006; Rademakers et al., 2007;
Spina et al., 2007; Guerreiro et al., 2008; Benussi et al., 2009; Yu
et al., 2010), but most cases are sporadic (Spillantini et al., 2000;
Lang, 2003; Uchihara and Nakayama, 2006).
Tau phosphoproteins bind to microtubules and are thought to
promote the assembly and stability of microtubules, thereby play-
ing a pivotal role in maintaining axonal transport as well as axonal
integrity (reviewed in Buee et al., 2000; Lee et al., 2001). In the
adult human central nervous system, six tau isoforms are produced
by alternative splicing (Goedert et al., 1989). Alternative splicing
of exons 2 and 3 results in the insertion of 0 (0N), 1 (1N) or
2 (2N) 29-amino acid long motifs near the amino terminus,
whereas splicing of exon 10 results in the inclusion of either 3
(3R) or 4 (4R) microtubule-binding domains in the carboxy ter-
minus. Splicing of exons 2, 3 and 10 is tightly regulated to main-
tain similar levels of 4R to 3R isoforms in the normal human brain
(Goedert and Jakes, 1990). The distinct tauopathies, however,
differ in their relative amounts of the six tau isoforms in insoluble
tau deposits. For example, in Alzheimer’s disease, both the 3R and
4R isoforms are abnormally phosphorylated, leading to aggrega-
tion of all six isoforms into paired helical filaments (Hong et al.,
1998). Inclusions in Pick disease contain predominantly 3R iso-
forms (Delacourte et al., 1996), while the major pathological tau
isoforms in progressive supranuclear palsy and corticobasal degen-
eration consist primarily of 4R (Arai et al., 2001; Forman et al.,
2002; Zhukareva et al., 2006). Based on the present pathology,
progressive supranuclear palsy was considered in the differential
diagnosis. Progressive supranuclear palsy is characterized by neur-
onal loss and the presence of tangles in globus pallidus, putamen,
substantia nigra, dentate and olivary nuclei (Hauw et al., 1990) as
well as a preponderance of 4R tau isoforms (Sergeant et al.,
1999). However, progressive supranuclear palsy presents much
later in life than does the syndrome described here, and severe
degeneration of cerebellar Purkinje cells seen in the present cases
is not usually seen in progressive supranuclear palsy.
Sarkosyl-insoluble tau extracted from brain tissue from the two
family members contained a clear preponderance of 4R isoforms,
which are also the predominant isoforms deposited in progressive
supranuclear palsy and corticobasal degeneration (Forman et al.,
2002; Zhukareva et al., 2006).
The morphological substrate(s) for mental retardation are di-
verse and may not have a common underlying basis. Of the
mental retardation syndromes, the neuropathologically best-
studied entities are Down’s syndrome, fragile X mental retard-
ation, Rett syndrome, MASA (mental retardation, aphasia, shuf-
fling gait and adducted thumbs) syndrome and West’s syndrome
(also called Partington syndrome, Proud syndrome and X-linked
lissencephaly). The most striking abnormalities in Down’s syn-
drome are b-amyloid deposits and the extensive presence of
neurofibrillary tangles similar to those seen in individuals with
Alzheimer’s disease (Glenner and Wong, 1984; Masters et al.,
1985; Wisniewski and Wrzolek, 1988) and may be caused by
overexpression of the APP gene, which is located on chromosome
21 (Cataldo et al., 2003). Other pathological correlates with
mental retardation include widespread dysmyelination in
Pelizaeus-Merzbacher disease (Seitelberger, 1970; Seitelberger
et al., 1996; Sima et al., 2009), aqueductal stenosis and ventricu-
lomegaly in MASA syndrome (Jouet et al., 1994; Vits et al.,
1994), lissencephaly (Gleeson et al., 1998; Pilz et al., 1998), cor-
tical heterotopias (Gleeson et al., 1998), cerebellar pathology
(Tentler et al., 1999; Bergmann et al., 2003; Huber, 2006) and
other severe disturbances of cerebral development (Eksioglu et al.,
1996). More subtle abnormalities, such as disturbance in matur-
ation of dendritic spines, may be the primary finding, as in Rett
syndrome (Jellinger et al., 1988; Armstrong, 2005) and in fragile X
mental retardation (Hinton et al., 1991; Wisniewski et al., 1991).
Many types of X-linked mental retardation, however, have either
shown no identifiable neuropathology or have not been character-
ized pathologically.
We speculate that the clinical deterioration noted in affected
members of the present family results from progressive
neuro-degeneration that is, at least in part, caused by the tau
deposition. Whether the tau deposition also is responsible for
the childhood-onset severe mental retardation is at this time un-
clear, since we only have pathological material from two
middle-aged affected males. However, since the tau deposition
is so widespread and intense, we believe it is likely to have been
long-standing in the affected individuals and have contributed to
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the mental retardation phenotype. It is possible that other factors
lead to mental retardation, and we cannot exclude the possibility
that these unknown determinants trigger the tau deposition.
The present pathological observations of a family with a form of
syndromic X-linked severe mental retardation, we believe, have
not been previously demonstrated. The demarcation between syn-
dromic and non-syndromic mental retardation is not precise, and
previously regarded non-syndromic forms of mental retardation
may have additional clinical findings that were not initially recog-
nized or emphasized, such as the cerebellar hypoplasia seen in
mutations of the oligophrenin 1 (OPHN1) gene (Philip et al.,
2003). The presence of seizures in most of the patients as well
as relatively late-onset motor deterioration, reminiscent of that
seen in patients with corticobasal degeneration, we believe, reflect
the underlying pathology in this family, and constitute distinctive
clinical findings that can help differentiate this syndrome from
other forms of X-linked mental retardation.
Analysis of another in-frame deletion (del 255–256) of SLC9A6
has shown that the mutant protein undergoes aberrant processing
and degradation in both the proteosomal and lysosomal compart-
ments (Roxrud et al., 2009). While the yeast homolog of SLC9A6,
Nhx1, has been shown to be important for both vesicular pH
regulation and intracellular vesicular targeting, the del 255–256
mutant protein does not appear to perturb vesicular pH (Gilfillan
et al., 2008; Roxrud et al., 2009), although depletion of both
SLC9A6 (sodium/hydrogen exchanger 6) and SLC9A9 (sodium/
hydrogen exchanger 9) does cause excessive acidification of
early endosomes (Roxrud et al., 2009). Therefore, perturbation
of endosomal pH does not appear to be the cause of cellular
pathology in SLC9A6-related mental retardation. However, a fur-
ther study will be needed to clarify the molecular and cellular
mechanisms of neuronal dysfunction and mental retardation, as
well as the conformational and processing effects on SLC9A6 of
the mutation found in the reported family.
The discovery that this family’s syndrome results from an
SLC9A6 mutation demonstrates that a disturbance in a membrane
transport protein can lead to tau aggregation. The del 255–256
mutant protein as well as wild-type SLC9A6 is transported by a
dynein-dependent mechanism (Roxrud et al., 2009). Other pro-
teins related to SLC9A6 have been shown to interact with elem-
ents of the cytoskeleton and may be critical for proper intracellular
vesicular trafficking (Orlowski and Grinstein, 2004). Together,
these observations suggest that the deposition of tau may be
mediated by the interaction with the mutant SLC9A6 protein.
The clear preponderance of 4R tau isoforms in the
sarkosyl-insoluble tau isolated from the patients examined here
is intriguing, since these are also the predominant isoforms
deposited in the neuropathologically similar progressive supra-
nuclear palsy and corticobasal degeneration syndromes (Forman
et al., 2002; Zhukareva et al., 2006). Progressive supranuclear
palsy and corticobasal degeneration are disorders of unknown
aetiology and most cases do not appear to have an obvious
Mendelian basis.
We speculate that the gene defect in this family may either
result in aberrant exon 10 splicing of MAPT, leading to the
observed tau isoform expression pattern, or somehow selectively
stabilize it, perhaps in the form of aggregates with the mutated
SLC9A6 protein. Disturbance in splicing is strongly suggested as a
mechanism in neurodegenerative disease by the recent discovery
that TDP-43 (also called TARDBP), an RNA-binding protein impli-
cated in exon skipping and transcriptional regulation (Buratti et al.,
2004; Mercado et al., 2005), is a major component of ubiquitin-
immunoreactive inclusions in sporadic amyotrophic lateral sclerosis,
in which aberrant splicing has been demonstrated (Neumann
et al., 2006). TDP-43 inclusions are also described in amyotrophic
lateral sclerosis with dementia, non-SOD1-associated familial
amyotrophic lateral sclerosis and in fronto-temporal lobar degen-
eration with ubiquitin inclusions (Arai et al., 2006; Cairns et al.,
2007; Neumann et al., 2007; Tan et al., 2007). The absence of
TDP-43 inclusions in our cases suggests that a different mechan-
ism underlies the generation of the tau isoform pattern in SLC9A6-
related mental retardation. Myotonic dystrophy 1 is another dis-
order in which perturbation in splicing is implicated as a major
mechanism in disease pathogenesis. Cerebral neurofibrillary de-
generation and mental retardation occur in severe cases of myo-
tonic dystrophy 1, and it is characterized by abnormal RNA
splicing of numerous genes, including MAPT, although the precise
mechanism(s) has not yet been identified (Maurage et al., 2005;
Leroy et al., 2006; Wang et al., 2007). Identification of a muta-
tion in SLC9A6 in the family presented in this report may provide
important insights not only into the underlying pathogenic mech-
anisms leading to this novel mental retardation and autism syn-
drome, but also to that of tau-associated dementias, such as those
important in the regulation and splicing of the MAPT gene and in
the processing of the tau metabolism abnormality.
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